98 related articles for article (PubMed ID: 34898072)
1. [Primary urothelial carcinoma of the prostate: A case report and review of the literature].
Han YF; Chen D; Peng L; Lai B; Huang HC; Wen XQ
Zhonghua Nan Ke Xue; 2020 Nov; 26(11):1010-1014. PubMed ID: 34898072
[TBL] [Abstract][Full Text] [Related]
2. Primary high-grade urothelial carcinoma of prostate with prostatic hyperplasia: a rare case report and review of the literature.
Liu L; Sun FZ; Zhang PY; Xiao Y; Yue X; Wang DM; Wang Q
Aging Male; 2023 Dec; 26(1):2252102. PubMed ID: 37642413
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
4. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
[TBL] [Abstract][Full Text] [Related]
5. Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.
Shirotake S; Kikuchi E; Tanaka N; Matsumoto K; Miyazaki Y; Kobayashi H; Ide H; Obata J; Hoshino K; Kaneko G; Hagiwara M; Kosaka T; Kanao K; Kodaira K; Hara S; Oyama M; Momma T; Miyajima A; Nakagawa K; Hasegawa S; Nakajima Y; Oya M
J Urol; 2015 Apr; 193(4):1122-8. PubMed ID: 25444957
[TBL] [Abstract][Full Text] [Related]
6. [Prostatic involvement by urothelial carcinoma in patients with bladder cancer and their implications in the clinical practice].
Huguet J
Actas Urol Esp; 2012 Oct; 36(9):545-53. PubMed ID: 22520044
[TBL] [Abstract][Full Text] [Related]
7. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
[TBL] [Abstract][Full Text] [Related]
8. "Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma.
Drakaki A; Pantuck A; Mhatre SK; Dhillon PK; Davarpanah N; Degaonkar V; Surinach A; Chamie K; Grivas P
Urol Oncol; 2021 Jan; 39(1):76.e15-76.e22. PubMed ID: 32778476
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Bellmunt J; Hussain M; Gschwend JE; Albers P; Oudard S; Castellano D; Daneshmand S; Nishiyama H; Majchrowicz M; Degaonkar V; Shi Y; Mariathasan S; Grivas P; Drakaki A; O'Donnell PH; Rosenberg JE; Geynisman DM; Petrylak DP; Hoffman-Censits J; Bedke J; Kalebasty AR; Zakharia Y; van der Heijden MS; Sternberg CN; Davarpanah NN; Powles T;
Lancet Oncol; 2021 Apr; 22(4):525-537. PubMed ID: 33721560
[TBL] [Abstract][Full Text] [Related]
10. The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder.
Meyer A; Ghandour R; Bergman A; Castaneda C; Wosnitzer M; Hruby G; Benson M; McKiernan J
J Urol; 2014 Sep; 192(3):696-701. PubMed ID: 24657802
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J
Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146
[TBL] [Abstract][Full Text] [Related]
12. Collision metastasis of prostatic adenocarcinoma and urothelial carcinoma of the bladder.
Sellman DP; Peard L; Simpson G; Lancaster K; Kavuri S; Terris M; Madi R
Urol Ann; 2018; 10(3):342-344. PubMed ID: 30089999
[TBL] [Abstract][Full Text] [Related]
13. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of Postoperative Adjuvant Chemotherapy for Patients with pT3N0M0 Upper Tract Urothelial Carcinoma.
Huang YC; Chen MF; Shi CS; Shindel AW; Huang CE; Pang ST; Chuang CK; Chen CS; Chang YH; Lin WY; Ho DR; Chin CC; Kuo YH; Wu CF
J Urol; 2015 Aug; 194(2):323-9. PubMed ID: 25796114
[TBL] [Abstract][Full Text] [Related]
15. Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy.
Zareba P; Patterson L; Pandya R; Margel D; Hotte SJ; Mukherjee SD; Elavathil L; Daya D; Shayegan B; Pinthus JH
Urol Oncol; 2014 Oct; 32(7):975-80. PubMed ID: 25027682
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
17. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
Moschini M; Shariat SF; Rouprêt M; De Santis M; Bellmunt J; Sternberg CN; Tombal B; Collette L
J Urol; 2018 May; 199(5):1149-1157. PubMed ID: 29158104
[TBL] [Abstract][Full Text] [Related]
18. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.
Tabayoyong W; Li R; Gao J; Kamat A
Urol Clin North Am; 2018 May; 45(2):155-167. PubMed ID: 29650132
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.
Porten S; Siefker-Radtke AO; Xiao L; Margulis V; Kamat AM; Wood CG; Jonasch E; Dinney CP; Matin SF
Cancer; 2014 Jun; 120(12):1794-9. PubMed ID: 24633966
[TBL] [Abstract][Full Text] [Related]
20. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer.
Porter MP; Kerrigan MC; Donato BM; Ramsey SD
Urol Oncol; 2011; 29(3):252-8. PubMed ID: 19450992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
